We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Read MoreHide Full Article
Bellerophon (BLPH - Free Report) stock declined almost 87% on Jun 5. This occurred soon after the company announced that a phase III study on its pipeline candidate, INOpulse, to treat fibrotic interstitial lung disease (fILD), failed to meet its primary endpoint.
The phase III REBUILD study was a randomized, double-blind, placebo-controlled study involving 145 fILD patients. The participants were divided into two groups — one received INOpulse at a dose of iNO45 and the other received placebo.
The primary objective of the study was to measure the change in moderate-to-vigorous physical activity using actigraphy after 16 weeks of treatment.
Disappointingly, the investigation could not meet its primary endpoint as the INOpulse group performed worse than the placebo group. Also, minimal differences were observed for the secondary endpoints between the two groups.
The study failed to achieve statistical significance for any of the secondary endpoints that included overall activity and Six Minute Walk Distance.
Bellerophon’s shares have plunged 4.8% year to date compared with the industry’s 7.3% decline.
Image Source: Zacks Investment Research
Given the results, management concluded that the outcomes of the REBUILD study did not align with those of the exploratory phase II study in the same patient population. Consequently, the company will not be moving forward with the study.
Bellerophon is developing two product candidates under its INOplus platform, both of which are in phase II studies. While one is being evaluated to treat pulmonary chronic obstructive pulmonary disease, the other is being assessed for sarcoidosis.
Bellerophon Therapeutics, Inc. Price and Consensus
The Zacks Consensus Estimate for Akero Therapeutics has narrowed from a loss of $3.46 per share to a loss of $2.78 for 2023 in the past 90 days. Shares of the company have nosedived 5.1% year to date.
AKRO’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 7.96%.
The consensus estimate for ADMA Biologics has narrowed from a loss of 19 cents to a loss of 9 cents per share for 2023 in the past 90 days. In the year so far, shares of the company have risen 3.9%.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
The consensus estimate for Omega Therapeutics has narrowed from a loss of $2.51 per share to a loss of $2.05 for 2023 in the past 90 days. Shares of the company have nosedived 32% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails
Bellerophon (BLPH - Free Report) stock declined almost 87% on Jun 5. This occurred soon after the company announced that a phase III study on its pipeline candidate, INOpulse, to treat fibrotic interstitial lung disease (fILD), failed to meet its primary endpoint.
The phase III REBUILD study was a randomized, double-blind, placebo-controlled study involving 145 fILD patients. The participants were divided into two groups — one received INOpulse at a dose of iNO45 and the other received placebo.
The primary objective of the study was to measure the change in moderate-to-vigorous physical activity using actigraphy after 16 weeks of treatment.
Disappointingly, the investigation could not meet its primary endpoint as the INOpulse group performed worse than the placebo group. Also, minimal differences were observed for the secondary endpoints between the two groups.
The study failed to achieve statistical significance for any of the secondary endpoints that included overall activity and Six Minute Walk Distance.
Bellerophon’s shares have plunged 4.8% year to date compared with the industry’s 7.3% decline.
Image Source: Zacks Investment Research
Given the results, management concluded that the outcomes of the REBUILD study did not align with those of the exploratory phase II study in the same patient population. Consequently, the company will not be moving forward with the study.
Bellerophon is developing two product candidates under its INOplus platform, both of which are in phase II studies. While one is being evaluated to treat pulmonary chronic obstructive pulmonary disease, the other is being assessed for sarcoidosis.
Bellerophon Therapeutics, Inc. Price and Consensus
Bellerophon Therapeutics, Inc. price-consensus-chart | Bellerophon Therapeutics, Inc. Quote
Zacks Rank and Other Stocks to Consider
Currently, Bellerophon sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the biotech sector are Akero Therapeutics (AKRO - Free Report) , ADMA Biologics (ADMA - Free Report) and Omega Therapeutics (OMGA - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Akero Therapeutics has narrowed from a loss of $3.46 per share to a loss of $2.78 for 2023 in the past 90 days. Shares of the company have nosedived 5.1% year to date.
AKRO’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 7.96%.
The consensus estimate for ADMA Biologics has narrowed from a loss of 19 cents to a loss of 9 cents per share for 2023 in the past 90 days. In the year so far, shares of the company have risen 3.9%.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
The consensus estimate for Omega Therapeutics has narrowed from a loss of $2.51 per share to a loss of $2.05 for 2023 in the past 90 days. Shares of the company have nosedived 32% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.